SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as the community discusses the potential impact of a failed Alzheimer's drug trial on its stock, despite its dominance in the obesity market with drugs like Wegovy, where community members speculate on the possibility of a price war. Some investors view the dip as a buying opportunity, emphasizing the company's strong fundamentals and long-term potential in the weight loss sector, while others worry about competition from other pharmaceutical companies. There is also discussion around potential acquisitions and partnerships.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending due to reports of a potential extension of Obamacare subsidies, sparking both bullish and bearish sentiments within the community. Bulls anticipate significant gains if the subsidies are extended, while bears express concerns about the company's long-term viability and potential challenges in improving medical loss ratios. Community members are actively discussing potential price targets, entry points, and the overall impact of policy changes on the healthcare sector.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending as discussions swirl around the company potentially allowing Bitcoin and Ethereum as loan collateral, a move seen by some as a major shift despite CEO Jamie Dimon's past skepticism towards crypto. The community is also buzzing about a possible silent war between JPMorgan and MicroStrategy ($MSTR), with some calling for a boycott of the bank. Technical analysis suggests JPM's chart indicates a possible support bounce or breakdown.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as community members discuss the potential impact of its new Gemini 3 model, with some suggesting it could be a game-changer in the AI race and drive further gains. Bullish sentiment is fueled by positive analyst ratings and Waymo's expansion, while some traders are closely watching for a potential pullback after the recent surge.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide ($WRD) is trending due to robotaxi revenue growth and global expansion milestones, including approvals for driverless operations in Abu Dhabi and partnerships with Uber and Grab. The community is buzzing about the company's potential to monetize AI and compete with Tesla in the robotaxi market. Discussions also highlight WeRide's strategic partnerships and the rapid development of China's autonomous driving technology.

Monad

Monad is trending as its public mainnet launch and token listing approaches, sparking excitement and debate within the crypto community. Discussions revolve around the token distribution process, potential for profit, and where to purchase, alongside speculation about a possible initial price surge and subsequent dip. Some users express concerns about it being a potential scam, while others highlight its listing on Coinbase as a positive sign.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending as its Qwen AI app reached 10 million downloads, driving optimism despite broader market AI skepticism. Community members are actively discussing the app's potential to rival ChatGPT and the implications for Alibaba's AI strategy. The news has sparked debate about the stock's valuation and future prospects within the competitive tech landscape.

Motorola Solutions, Inc. engages in the provision of communication infrastructure, devices, accessories, software, and services. It operates through the Products and Systems Integration and Software and Services segments. The Products and Systems Integration segment includes a portfolio of infrastructure, devices, accessories, and video security devices, and the implementation and integration of such systems, devices, and applications. The Software and Services segment focuses on the public safety and enterprise Command Center Software, unified communications applications, and video software solutions. The company was founded on September 25, 1928 and is headquartered in Chicago, IL.

Motorola Solutions Inc

MSI is trending due to community focus on technical analysis, particularly positive divergence and significant dark pool activity suggesting a potential oversold bounce. Traders are pointing to a large dark pool print as a sign of a bottom and reversal. The stock's oversold condition and potential for a bounce are key talking points.

Molina Healthcare, Inc. engages in the provision of health care services. It operates through the following segments: Medicaid, Medicare, Marketplace, and Other. The company was founded by C. David Molina in 1980 and is headquartered in Long Beach, CA.

Molina Healthcare Inc

MOH is trending as the community discusses its recent rating adjustments from various firms and a significant price drop following disappointing earnings, which missed estimates due to rising medical costs. Community members are weighing the potential for a rebound, citing the company's balance sheet, while others express concerns about sector-wide challenges and potential downgrades. Discussions also revolve around the impact of Medicaid and Medicare policies on the company's revenue streams.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Biogen ($BIIB) is trending due to Novo Nordisk's Alzheimer's drug trial failure, boosting interest in BIIB's CNS pipeline. The community is discussing Biogen's potential upside in the Alzheimer's space and recent analyst upgrades. Biogen's strategic focus on CNS and Alzheimer's treatments is being highlighted amid renewed interest in the sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

INmune Bio (INMB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

INmune Bio (INMB) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

INmune Bio (INMB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

INmune  slides again as Scotiabank, RJ cut ratings after Alzheimer’s drug miss

Investing.com --  INmune Bio  (NASDAQ:INMB) shares fell another 6% to about $2.17 on Tuesday after brokerages downgraded the stock, saying failure of the company’s experimental Alzheimer’s drug XPro in a mid‑stage trial sharply weakens its investment case.

INmune Bio Inc. (INMB) on Monday said that its experimental drug XPro did not show any effects in the intent-to-treat population in a mid-stage study evaluating its effectiveness in early Alzheimer’s Disease (AD) with biomarkers of inflammation.INmune’s stock fell about 59% in morning trade at the time of writing.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/30/3107380/0/en/INmune-Bio-Reports-Key-Findings-from-Phase-2-MINDFuL-Trial-of-XPro-in-Early-Alzheimer-s-Disease.html">trial </a>enrolled 208 participants with early-stage Alzheimer’s to asses the drug’s potential in slowing cognitive decline by tackling neuroinflammation.The primary endpoint of the study was a change in cognition over 6 months on the Early Mild Alzheimer’s Cognitive Composite (EMACC). EMACC is a tool used in clinical trials and research to assess cognitive changes in individuals with early or mild Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI).The primary endpoint was not met in the intent-to-treat population.However, changes in clinical measures of cognition, behavior, and an AD-related biomarker demonstrated a benefit in a subpopulation of 100 early Alzheimer's patients with inflammation biomarkers who were treated with XPro, compared to patients treated with placebo, the company said.CEO RJ Tesi said that the findings lay the foundation for advancing XPro as a “promising treatment option” for Alzheimer’s.XPro treatment was safe and well-tolerated, the company added.<a href="https://stocktwits.com/symbol/INMB">INmune</a> now intends to schedule an end-of-mid-stage meeting with the U.S. Food and Drug Administration (FDA) in the last quarter of 2025 to define the path forward for a pivotal trial to support XPro approval in early Alzheimer’s.Despite the drop in INMune stock during Monday’s trading session, retail sentiment around the stock is trending in the ‘extremely bullish’ territory on Stocktwits.INMB stock is down by about 53% this year and by about 74% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/moderna-flu-vaccine-show-positive-results-in-late-stage-trial/chmZitPRR72">Moderna Stock Surges Pre-Market As Flu Vaccine Shows Positive Results In Late-Stage Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial

The primary endpoint of the study was not met in the intent-to-treat population, the company said. 

Equity

INmune Bio stock plummets after mixed Phase 2 Alzheimer’s trial results

Investing.com --  INmune Bio  Inc. (NASDAQ:INMB) stock fell 60% in pre-market trading Monday after the company reported mixed results from its Phase 2 MINDFuL trial of XPro in early Alzheimer’s disease patients.

INmune Bio Inc. (INMB) on Friday said that it entered into securities purchase agreements with two healthcare-focused institutional investors for the purchase and sale of 3 million shares of its common stock.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/27/3106725/0/en/INmune-Bio-Inc-Announces-Approximately-19-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html">said</a> that it would sell 3 million shares of its common stock in a registered direct offering at a purchase price of $6.30 per share. The proceeds from the offering are expected to be about $19 million, excluding costs such as fees to the placement agency Alliance Global Partners.<a href="https://stocktwits.com/symbol/INMB">INmune Bio</a> said that it intends to use the proceeds from the offering for working capital purposes and general corporate purposes.The closing of the offering is expected to occur on or about June 20.INMB shares are down 19% on Friday afternoon.&nbsp;On Stocktwits, retail sentiment around INmune Bio is unmoved within the ‘extremely bullish’ territory over the past 24 hours, while retail chatter stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_27_at_2_24_21_PM_png_cb3ab03d42.webp" alt="INMB's Sentiment Meter and Message Volume as of 2:25 p.m. ET on June 27, 2025 | Source: Stocktwits" width="625" height="64"><figcaption>INMB's Sentiment Meter and Message Volume as of 2:25 p.m. ET on June 27, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the company is headed to a year-long downtrend.<stembedurl>https://stocktwits.com/CharlesIV/message/619287462</stembedurl>Another user opined that a stock offering before data results is “sketchy.”<stembedurl>https://stocktwits.com/EddieGon/message/619286742</stembedurl>INmune Bio is slated to present topline results from its mid-stage Alzheimer’s trial, the MINDFuL study, on Monday. The trial is testing its lead drug candidate XPro in patients with mild cognitive impairment or Alzheimer’s disease with brain inflammation.The MINDFuL study will compare XProTM to placebo to find out whether XPro affects memory, functioning, and behavior. The study will also evaluate whether XPro is safe and tolerable.INMB stock is up by 9% this year and down by about 41% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/gilead-stock-rises-on-us-supreme-court-ruling-in-favor-of-health-insurers-covering-preventive-care/chmWPN2RRe5">Gilead Stock Rises On US Supreme Court Ruling In Favor Of Health Insurers Covering Preventive Care</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

INmune Bio Stock Slumps On 3M Share Offering Ahead Of Mid-stage Trial Data, But Retail Remains Bullish 

The company said that it would sell 3 million shares of its common stock in a registered direct offering at a purchase price of $6.30 per share.

INmune Bio saw its stock surge 75% in after-hours trading Thursday after disclosing plans to unveil topline results from its Phase 2 Alzheimer’s trial on Monday.The company will present findings from its MINDFuL study, a placebo-controlled trial testing its lead drug candidate XPro in patients showing early signs of Alzheimer’s.&nbsp;The study participants consisted of 208 patients diagnosed with mild cognitive impairment or mild Alzheimer's disease.&nbsp;The average age of the participants was 72 years. In all of the participants, biomarkers of inflammation were present.&nbsp;The inflammatory biomarkers observed were elevated C-reactive protein levels, along with increased ESR and higher HbA1c values and genetic markers such as the APOE ε4 allele.&nbsp;Participants were randomized 2-to-1 to receive weekly doses of XPro or a placebo for just under six months.The main goal of the study is to assess cognitive change using a custom measurement tool called the early and mild Alzheimer's cognitive composite&nbsp;(EMACC), designed to detect subtle shifts in early-stage Alzheimer’s.&nbsp;Previous data showed the EMACC aligns well with other standard assessments like MMSE and CDR-SB.The company reported that over two-thirds of participants carried the APOE ε4 gene, and nearly two-thirds qualified through more than one biomarker.&nbsp;Roughly 72% of patients screened for the trial were not enrolled, mostly due to more advanced disease.In addition to cognitive scoring, the study includes secondary measures such as evaluations of daily living, neuropsychiatric symptoms, and biological markers.XPro is part of the company’s broader immune-targeting drug platform, which focuses on conditions believed to stem from chronic inflammation.&nbsp;<a href="https://stocktwits.com/symbol/INMB">INmune</a> is also exploring XPro for use in depression, alongside other programs for cancer and rare skin disorders.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 344% surge in 24-hour message volume.One user said that the timing of the announcement indicated confidence from the company, noting that results slated for early Monday were unlikely to disappoint.<stembedurl>https://stocktwits.com/winefan/message/619189685</stembedurl>They also referenced commentary from&nbsp;“pharma bro”&nbsp;Martin&nbsp;Shkreli, who previously stated that if the drug proves effective, the stock could surge dramatically, possibly even reaching triple-digit levels.Another user noted the pre-market Monday scheduling as a potentially encouraging signal but said they wouldn’t celebrate until the actual data is released.<stembedurl>https://stocktwits.com/BoilerKing/message/619167991</stembedurl>The stock has risen 27.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

INmune Bio Skyrockets After-Hours On Alzheimer’s Trial Buzz; Retail Bulls Bet Big Before Data Reveal Next Week

INmune is also developing XPro for treatment-resistant depression and exploring other immune-driven conditions like cancer and rare skin disorders.

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimers Trial with Vivo, a Novel genAI Clinical Trial Control Tower

OmniScience and INmune Bio (NASDAQ: INMB) today announced a pioneering partnership to revolutionize operations for INmune Bios global Phase 2 Alzheimers disease (AD) clinical trial (the AD02 trial...

<ul><li>Alzheimer’s Drug Market Faces Urgent Need for Innovative Therapies Beyond Big Pharma</li><li>Small Biotech Companies Lead the Charge with Disruptive Approaches to Treating Alzheimer’s</li></ul>Alzheimer’s disease has been one of the most challenging conditions for the pharmaceutical industry to address. While companies like&nbsp;Biogen (BIIB) and&nbsp;Eli Lilly (LLY) have made notable strides with drugs like&nbsp;Aduhelm and&nbsp;Donanemab, which target amyloid plaques, breakthrough treatments that offer substantial cognitive improvements remain elusive. Despite these advancements, many of these drugs focus on slowing disease progression rather than providing a cure, and their impact has been limited.Historically, much of the innovation in Alzheimer’s research has come from smaller biotech companies, many of which are eventually acquired by larger pharmaceutical firms like BIIB and LLY. However, the results from these acquisitions have often not met expectations, leaving room for new players to disrupt the market with more innovative approaches.For investors looking for broader exposure to the biotech sector, the&nbsp;XBI ETF (SPDR S&amp;P Biotech ETF) offers a more diversified way to play the space. XBI tracks an equal-weighted index of U.S. biotech stocks, providing exposure to both large players like Biogen and smaller upstarts working on novel treatments. The ETF has seen strong performance recently, driven by optimism around biotech innovation in areas like Alzheimer’s, oncology, and rare diseases. While individual biotech stocks can be volatile, XBI spreads the risk across a broader portfolio, making it a compelling option for those looking to invest in the sector without taking on the higher risk of single-stock picks.The Alzheimer’s drug market is projected to reach $13.7 billion by 2029, and despite the presence of big pharma, there remains a significant opportunity for companies with novel therapies to address this unmet need. In this article, we examine three small-cap biotech players —&nbsp;Cassava Sciences (SAVA),&nbsp;INmune Bio (INMB), and&nbsp;Annovis Bio (ANVS) — that are working on breakthrough Alzheimer’s therapies. We will break down their potential by analyzing the good, the bad, the ugly, and their overall investability.&nbsp;<h4>Read Now:&nbsp;<a href="https://wealthyvc.com/featured/20m-healthcare-stock-breaks-out-after-rising-1700-on-medicare-and-medicaid-clearance-heres-whats-being-announced-in-the-coming-months-in-a-25x-larger-market/">This $20m Company Soars 1,700% on Medicare &amp; Medicaid Clearance— Find out What’s Being Announced in the Coming Months in a Market 25X Larger</a></h4>&nbsp;<h3>Cassava Sciences (SAVA)&nbsp;<a href="https://stocktwits.com/symbol/SAVA">[Follow on Stocktwits.com]</a></h3><h4>The Lowdown:</h4>Cassava Sciences is developing Simufilam, a drug that targets a unique protein misfolding pathway in Alzheimer’s disease. Unlike traditional therapies that focus solely on amyloid plaques, Simufilam aims to correct the shape of the protein Filamin A, which may influence multiple Alzheimer’s disease processes. This innovative approach could potentially address multiple aspects of the disease.Cassava has faced a mix of positive and negative news. Its Phase 2 trial results showed cognitive improvement in Alzheimer’s patients, generating optimism. However, allegations of data manipulation have cast a cloud over the company’s achievements, leading to regulatory scrutiny and volatility in the stock.<h4>The Good:</h4>Simufilam’s unique approach could disrupt the Alzheimer’s drug market if Phase 3 trials confirm its efficacy. With Alzheimer’s treatments falling short of significant impact, a drug that improves cognitive function would undoubtedly capture massive attention. Additionally, Cassava’s high short interest could lead to a short squeeze if positive news emerges, providing an opportunity for investors to capitalize on sharp price movements. Notably, if the drug succeeds, the company’s stock could skyrocket, presenting massive upside potential for investors.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_03_at_11_27_24_AM_67dc564cb2.png" alt="Screenshot 2024-10-03 at 11.27.24 AM.png"><h4>The Bad:</h4>The allegations of data manipulation have raised questions about the integrity of Cassava’s research. Although the company has denied wrongdoing, the concerns could weigh heavily on investor confidence until the Phase 3 data is released. Moreover, Alzheimer’s disease is notoriously difficult to treat, and even promising drugs can fail in late-stage trials.<h4>The Ugly:</h4>Cassava’s main challenge is that it’s a one-trick pony. The company’s future is almost entirely dependent on the success of Simufilam. If the Phase 3 trials show negative results, the stock could plummet, potentially wiping out investors. Cassava lacks diversification in its pipeline, and failure could be disastrous for the company’s long-term viability.<h4>Investability:</h4>Cassava Sciences is a high-risk, high-reward stock. For investors willing to take on significant risk, the potential upside of Simufilam is enormous. However, given the controversies surrounding the company, a cautious approach is warranted. Those looking for long-term gains should monitor the Phase 3 results closely before making any major investments.&nbsp;<h3>INmune Bio (INMB)&nbsp; <a href="https://stocktwits.com/symbol/inmb">[Follow on Stocktwits.com]</a></h3><h4>The Lowdown:</h4>INmune Bio is taking a unique approach to treating Alzheimer’s by focusing on neuroinflammation rather than the traditional amyloid or tau pathways. The company’s lead drug, XPro1595, is designed to reduce brain inflammation by neutralizing soluble TNF (sTNF), a cytokine that drives chronic inflammation in Alzheimer’s patients. This could potentially offer a complementary treatment to existing therapies. In addition to its Alzheimer’s focus, INmune Bio has a strong oncology portfolio, which includes its INKmune platform aimed at improving cancer immunotherapy.Recent clinical data on XPro1595 has been promising, with the drug showing efficacy in reducing neuroinflammation. The company is preparing for larger trials in 2025, which could solidify its position in the Alzheimer’s space.<h4>The Good:</h4>INmune Bio’s focus on neuroinflammation sets it apart from other Alzheimer’s treatments. Reducing inflammation has shown to be a crucial factor in preventing cognitive decline, and XPro1595’s early data suggests it could be a game-changer in this area. Furthermore, INmune Bio’s diversified portfolio, including its oncology platform, gives it additional avenues for growth beyond Alzheimer’s, reducing its risk compared to Cassava Sciences.<h4>The Bad:</h4>Despite the promise of XPro1595, the drug is still in early-stage trials, and it could take years before it reaches the market. The road to FDA approval is long and fraught with challenges, and investors will need to be patient as the company moves through its clinical development phases.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_03_at_11_28_27_AM_bf6e45fe54.png" alt="Screenshot 2024-10-03 at 11.28.27 AM.png"><h4>The Ugly:</h4>One of the biggest risks for INmune Bio is its reliance on early-stage data. While XPro1595 has shown promise, it has not yet demonstrated long-term efficacy in larger trials. Any setbacks in the trial process could delay the drug’s development and hurt the company’s stock.<h4>Investability:</h4>INmune Bio offers the best reward-to-risk ratio among the three companies. With a diversified portfolio and a promising Alzheimer’s treatment, INmune Bio is well-positioned to capitalize on breakthroughs in both neuroinflammation and oncology. Investors looking for a biotech stock with high upside potential but less concentrated risk compared to Cassava Sciences may find INmune Bio to be a compelling option.<h4>Read Now:&nbsp;<a href="https://wealthyvc.com/featured/20m-healthcare-stock-breaks-out-after-rising-1700-on-medicare-and-medicaid-clearance-heres-whats-being-announced-in-the-coming-months-in-a-25x-larger-market/">This $20m Company Soars 1,700% on Medicare &amp; Medicaid Clearance— Find out What’s Being Announced in the Coming Months in a Market 25X Larger</a></h4>&nbsp;<h3>Annovis Bio (ANVS)&nbsp;&nbsp;<a href="https://stocktwits.com/symbol/ANVS">[Follow on Stocktwits.com]</a></h3><h4>The Lowdown:</h4>Annovis Bio is targeting Alzheimer’s with Buntanetap, a drug that aims to reduce multiple neurotoxic proteins, including amyloid, tau, and alpha-synuclein. By taking a multi-pronged approach, Annovis hopes to provide a more comprehensive treatment for neurodegenerative diseases like Alzheimer’s and Parkinson’s.The company recently reported positive early-stage trial results, showing that Buntanetap improved cognition in patients with Alzheimer’s. With a Phase 2 trial in progress, Annovis Bio is positioning itself as a serious contender in the Alzheimer’s space.<h4>The Good:</h4>Buntanetap’s ability to target multiple neurotoxic proteins gives it an advantage over single-target therapies. The early data showing cognitive improvement has bolstered investor confidence, and the drug’s potential to address both Alzheimer’s and Parkinson’s opens up additional market opportunities. If Buntanetap continues to perform well in clinical trials, Annovis Bio could see substantial growth.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_03_at_11_29_39_AM_fafa150775.png" alt="Screenshot 2024-10-03 at 11.29.39 AM.png"><h4>The Bad:</h4>However, Annovis Bio is still in the early stages of its clinical trials, and the road to commercialization is long. The company will need to demonstrate consistent efficacy in larger trials before it can become a serious player in the Alzheimer’s market. Additionally, competition from other multi-target therapies could limit its market share.<h4>The Ugly:</h4>Like many small biotech companies, Annovis Bio is reliant on the success of a single drug candidate. If Buntanetap fails in its clinical trials, the company could struggle to recover. Investors should be aware of the high risk associated with this stock.<h4>Investability:</h4>Annovis Bio presents a speculative but potentially rewarding investment. The company’s multi-target approach could offer greater efficacy than traditional Alzheimer’s treatments, but it remains a high-risk bet. Investors should monitor the progress of its clinical trials closely before making any significant investments.<h3>Conclusion</h3>The Alzheimer’s drug market is poised for disruption, and companies like Cassava Sciences, INmune Bio, and Annovis Bio are leading the charge with innovative treatments. While these stocks come with substantial risks, the potential rewards could be life-changing — both for patients and investors. For those willing to take a gamble on the future of Alzheimer’s treatment, these companies offer a unique opportunity to not only achieve significant financial gains but also to contribute to a cause that could improve millions of lives.Of the three, INmune Bio stands out for its diversified portfolio and promising early data, making it a potentially safer bet. Cassava Sciences offers the most dramatic upside but comes with higher risks due to its single-drug focus. Annovis Bio, while speculative, offers intriguing potential with its multi-targeted approach.As always, investors should weigh the risks and rewards carefully but know that their investments could make a profound difference in the fight against one of the most challenging diseases of our time.&nbsp;<h4>Read Now:&nbsp;<a href="https://wealthyvc.com/featured/20m-healthcare-stock-breaks-out-after-rising-1700-on-medicare-and-medicaid-clearance-heres-whats-being-announced-in-the-coming-months-in-a-25x-larger-market/">This $20m Company Soars 1,700% on Medicare &amp; Medicaid Clearance— Find out What’s Being Announced in the Coming Months in a Market 25X Larger</a></h4>&nbsp;This author or the principals of WVC do not hold any of the stocks mentioned in this article.&nbsp;<ul><li><a href="http://www.stocktwits.com/wealthyvc">Follow us on Stocktwits</a>&nbsp;</li><li><a href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a></li><li>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at&nbsp;Invest@WealthyVC.com</li></ul>

Big Pharma’s $13.7B Alzheimer’s Drug Market Has a Progress Problem: Here Are Three Small-Cap Biotech Stocks That Could Disrupt the Market

Discover how small-cap biotech companies like Cassava Sciences, INmune Bio, and Annovis Bio are shaking up the $13.7 billion Alzheimer’s drug market with innovative treatments. Explore their potential for high-risk, high-reward gains

Small biotech firms like Cassava Sciences, INmune Bio, and Annovis Bio are developing innovative Alzheimer’s treatments, disrupting big pharma’s dominance in the $13.7B market. For those targeting groundbreaking therapies, high-risk, high-reward investments lie ahead.


Inmune Bio's Clinical Advancements Secure Buy Rating from Analyst Jason McCarthy

Inmune Bio (INMB Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from M...

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. Its product pipeline includes INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell on September 25, 2015 and is headquartered in Boca Raton, FL.

Current Price	$1.51
Prev Close	$1.49
Open	$1.51
Dividend Yield	0.00%
50-Day Moving Average	$1.82
Beta	1.43
Avg. Volume	360,161.26
PE Ratio	-0.71

52-Week High	$11.64
52-Week Low	$1.38
Market Capitalization	$40.14M
EPS (Annual)	-$2.11
Price to Book	1.58
Revenue Per Employee	$636.36
Enterprise Value/EBITDA	N/A

INMB
INmune Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INMB News

INMBINmune Bio Inc